The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
The effect of LNS8801 alone and in combination with pembrolizumab in patients with metastatic uveal melanoma.
 
Alexander Noor Shoushtari
Consulting or Advisory Role - Bristol-Myers Squibb; Immunocore; Novartis
Research Funding - Bristol-Myers Squibb; Checkmate Pharmaceuticals (Inst); Foghorn Therapeutics (Inst); Immunocore; Linnaeus Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Polaris; Targovax (Inst); Xcovery
Patents, Royalties, Other Intellectual Property - UpToDate
 
Marya F. Chaney
Employment - Merck
Stock and Other Ownership Interests - Merck
Travel, Accommodations, Expenses - Merck
 
Justine Vanessa Cohen
Consulting or Advisory Role - Regeneron; Sanofi/Regeneron
 
Tina Garyantes
Employment - Linnaeus Therapeutics
Leadership - Linnaeus Therapeutics
Stock and Other Ownership Interests - Linnaeus Therapeutics (Inst)
Research Funding - Linnaeus Therapeutics
Patents, Royalties, Other Intellectual Property - Linnaeus Therapeutics
Travel, Accommodations, Expenses - Linnaeus Therapeutics
 
Jessica Jiyeong Lin
Honoraria - OncLive; Pfizer
Consulting or Advisory Role - Bayer; Blueprint Medicines; C4 Therapeutics; Elevation Oncology; Genentech; Mirati Therapeutics; Novartis; Nuvalent, Inc.; Regeneron; Turning Point Therapeutics
Research Funding - Bayer (Inst); Elevation Oncology (Inst); Hengrui Therapeutics (Inst); Linnaeus Therapeutics (Inst); Neon Therapeutics (Inst); Novartis (Inst); Nuvalent, Inc. (Inst); Relay Therapeutics (Inst); Roche (Inst); Turning Point Therapeutics (Inst)
Travel, Accommodations, Expenses - Pfizer
 
Jeffrey Joseph Ishizuka
Stock and Other Ownership Interests - Jounce Therapeutics; Kronos Bio
Consulting or Advisory Role - Danger Bio; Phenomic AI; Rheos Medicines; Tango Therapeutics; Two River Group
Research Funding - AstraZeneca/MedImmune
Patents, Royalties, Other Intellectual Property - I am an inventor on a patent on approaches targeting dsRNA sensing titled: "MODULATING dsRNA EDITING, SENSING, AND METABOLISM TO INCREASE TUMOR IMMUNITY AND IMPROVE THE EFFICACY OF CANCER IMMUNOTHERAPY AND/OR MODULATORS OF INTRATUMORAL INTERFERON".
 
Alain C. Mita
Speakers' Bureau - Genentech
 
Monica M. Mita
No Relationships to Disclose
 
Carolyn Muller
Consulting or Advisory Role - GlaxoSmithKline
Research Funding - agenus (Inst); AstraZeneca (Inst); Genmab (Inst); Incyte (Inst); Linnaeus Therapeutics (Inst); Merck (Inst); Roche/Genentech (Inst); TapImmune Inc. (Inst); VBL Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - Have a pending patent on the cancer use for R-ketorolac - not yet its own new drug. (Inst)
Other Relationship - Department of Defense; FDA; NCI; NCI
 
Christopher Natale
Employment - Linnaeus Therapeutics
Leadership - Linnaeus Therapeutics
Stock and Other Ownership Interests - Linnaeus Therapeutics
Patents, Royalties, Other Intellectual Property - Inventor on Patents held by Linnaeus Therapeutics and the University of Pennsylvania
 
Marlana M. Orloff
Consulting or Advisory Role - Delcath Systems; IDEAYA Biosciences; Immunocore; TriSalus Life Sciences
Speakers' Bureau - Bristol-Myers Squibb
Research Funding - Bristol-Myers Squibb (Inst); Delcath Systems (Inst); IDEAYA Biosciences (Inst); IDEAYA Biosciences (Inst); Immunocore (Inst); Linnaeus Therapeutics (Inst); Plexxikon (Inst)
 
Kyriakos P. Papadopoulos
Consulting or Advisory Role - Basilea; Bicycle Therapeutics; Turning Point Therapeutics
Research Funding - 3D Medicines (Inst); Abbvie (Inst); ADC Therapeutics (Inst); Amgen (Inst); Anheart Therapeutics (Inst); Bayer (Inst); Bicycle Therapeutics (Inst); Biontech (Inst); Calithera Biosciences (Inst); Daiichi Sankyo (Inst); EMD Serono (Inst); F-star (Inst); Incyte (Inst); Jounce Therapeutics (Inst); Kezar Life Sciences (Inst); Lilly (Inst); Linnaeus Therapeutics (Inst); MabSpace Biosciences (Inst); MedImmune (Inst); Merck (Inst); Mersana (Inst); Mirati Therapeutics (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Regeneron (Inst); Syros Pharmaceuticals (Inst); Tempest Therapeutics (Inst); Treadwell Therapeutics (Inst)
 
Sapna Pradyuman Patel
Honoraria - Delcath Systems; Emory University
Consulting or Advisory Role - Bristol Myers Squibb; Castle Biosciences; Delcath Systems; immatics; Immunocore; Novartis; Pfizer; Replimune; TriSalus Life Sciences
Research Funding - Bristol-Myers Squibb (Inst); Foghorn Therapeutics (Inst); InxMed (Inst); Lyvgen Biopharma (Inst); Novartis (Inst); Provectus (Inst); Seagen (Inst); Syntrix Biosystems (Inst); TriSalus Life Sciences (Inst)
Travel, Accommodations, Expenses - InxMed; TriSalus Life Sciences
 
Jordi Rodon Ahnert
Consulting or Advisory Role - AADi; Avoro Capital Advisors; Boxer Capital; Chinese University of Hong Kong; Clarion Healthcare; Columbus Venture Partners; Cullgen; Debiopharm Group; Ellipses Pharma; Envision Pharma Group; iOnctura; Macrogenics; Merus; Monte Rosa Therapeutics; Monte Rosa Therapeutics; Oncology One; Pfizer; Sardona Therapeutics; Tang Advisors; Vall d'Hebron Institute of Oncology/Ministerio De Empleo Y Seguridad Social
Research Funding - AADi (Inst); Amgen (Inst); Bayer (Inst); Bicycle Therapeutics (Inst); BioAtla (Inst); BioMed Valley Discoveries (Inst); Black Diamond Therapeutics (Inst); Blueprint Medicines (Inst); Cellestia Biotech (Inst); Curis (Inst); CytomX Therapeutics (Inst); Deciphera (Inst); Fore Biotherapeutics (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Hummingbird (Inst); Hutchison MediPharma (Inst); IDEAYA Biosciences (Inst); Kelun (Inst); Linnaeus Therapeutics (Inst); Loxo (Inst); Merck Sharp & Dohme (Inst); Merus (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Nuvation Bio (Inst); Pfizer (Inst); Roche (Inst); Spectrum Pharmaceuticals (Inst); Symphogen (Inst); Taiho Pharmaceutical (Inst); Takeda/Millennium (Inst); Tango Therapeutics (Inst); Vall d'Hebron Institute of Oncology/Cancer Core Europe (Inst); Yingli Pharma (Inst)
Travel, Accommodations, Expenses - ESMO
Other Relationship - Vall d'Hebron Institute of Oncology/Ministerio De Empleo Y Seguridad Social